NICE rejects NHS funding for Portola’s Ondexxya
NICE says there is “no direct evidence” that the drug is better than existing treatment
Read More
Tag: Portola
US approval for Portola’s BevyxXa
Portola Pharmaceuticals’ BevyxXa has been cleared by the US Food and Drug Administration for preventing blood clots in hospitalised patients.
Read More
EU to review Portola’s blood-thinner antidote
The group is seeking conditional approval for the drug’s use when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding and for patients requiring urgent or emergency surgery.
Read More
Portola’s blood thinner antidote turned away by FDA
Portola has been dealt a blow after its anticoagulation reversal drug AndexXa was rejected by the US Food and Drug Administration.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
